Portal Biotech
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $43.2Mattributed |
|---|---|
| Latest round | series-a, $32.1M, 2025-06-01attributed |
| Founded | 2021 |
| Headquarters | London, GB |
| Industry | bio |
| Stage | series-a |
| Website | portalbiotech.com |
Portal Biotech develops nanopore-based technology for single-molecule protein sequencing and analysis, reading proteins directly rather than inferring them. It serves researchers and biopharma teams in proteomics, diagnostics, and drug discovery. Its nanopore approach reads full-length proteins at single-molecule resolution.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | series-a | $32.1M | undisclosed |
Detected tech stack
Nginx, WordPress, Yoast SEO 27.6, reCAPTCHA, Google Analytics, Google Tag Manager, DoubleClick Floodlight, Vercel Speed Insights, PHP, MySQL, Vue.js 3.5.6
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $32.1M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $43.2M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | portalbiotech.com, read 2026-05-07 |
| Description | self-reported | portalbiotech.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.